78 stories found
The law firm Levi & Korsinsky has announced upcoming deadlines for investors seeking to lead securities fraud class action lawsuits against several publicly traded companies. Shareholders holding stock in firms including Intuit, Regeneron, and Wix.com are being notified of potential legal claims and filing windows.
Connor Hill won first place at the 2026 Regeneron Science Talent Search competition. His research classified noble polyhedra, identifying two infinite families and 146 isolated examples.
A review of the healthcare sector in July shows strong performance from Regeneron and DexCom, while Moderna and managed-care stocks experienced a retreat.
Wall Street experienced market fluctuations following the Federal Reserve's interest rate decision and new inflation figures. Major tech companies like Microsoft, Apple, and Meta reported earnings, with investor focus on AI spending and its impact on future growth.
Several companies, including Plexus, Preformed Line Products, Endeavour Silver, Cactus, Spok, Insperity, Arxis, CONMED, and Everest Group, reported their latest quarterly earnings, with most beating analyst expectations for EPS and revenue. Starbucks, however, saw a significant decline in international revenue, and Pilgrim's Pride missed on both EPS and revenue.
Regeneron Pharmaceuticals (REGN) experienced a setback in its second quarter due to disappointing results from recent clinical trials, affecting its financial performance.
Eli Lilly and Regeneron have been selected by the FDA to participate in a new pilot program designed to boost U.S. drug manufacturing. This initiative aims to speed up the review process for new manufacturing facilities.
The US government has imposed new sanctions on Cuba and blacklisted Nigerian individuals and firms for ISIS funding. Meanwhile, Italy seeks to repair its relationship with the US, and South Korea hosts a conference in Washington to expand defense cooperation.
Regeneron's antibody therapy has gained support from the World Health Organization for use during an ongoing Ebola outbreak.
An analysis investigates if Regeneron Pharmaceuticals' stock is underperforming when compared to the Dow Jones Industrial Average.
Following recent Q1 updates, analysts from Morgan Stanley, Canaccord, Deutsche Bank, and Bernstein have adjusted price targets for several companies. This includes both increases for firms like NextEra Energy, Park Hotels & Resorts, Venture Global, Devon Energy, Golar LNG, ConocoPhillips, Chevron, and Arrowhead Pharmaceuticals, and cuts for Joby Aviation and Baker Hughes, with Canaccord citing a disappointing event for Regeneron Pharmaceuticals.
CNBC reports on several stocks, including Regeneron, Dominion, Mobileye, and Viking, that are experiencing the largest movements in midday trading.
Nikola Veselinov, an eleventh-grader from Sofia's Mathematical High School, has won the Regeneron ISEF, the largest global science and engineering competition for high school students, held in Phoenix, Arizona.
Regeneron's Libtayo combination therapy has encountered a late-stage trial setback in its competition against Merck's Keytruda.
The article discusses whether Regeneron is a good investment following the FDA's approval of its gene therapy designed to restore hearing.
A range of companies, including Landmark Bancorp, The Cheesecake Factory, and Mattel, have announced their latest quarterly financial results, detailing their earnings per share and revenue figures.
Regeneron Pharmaceuticals reported first-quarter earnings that topped analyst estimates, largely attributed to the strong momentum of its drug Dupixent.
Israel and Lebanon have agreed to extend their ceasefire, reportedly by three weeks, following discussions facilitated by the United States. This extension comes amidst hopes for a potential peace deal in the region.
Amid escalating tensions with Iran, European nations and the UK are discussing plans to secure the Strait of Hormuz. The US has increased its naval presence in the region and issued warnings to Iran, with reports of a US naval blockade advancing into international waters.
An earnings preview outlines expectations for Regeneron Pharmaceuticals' upcoming financial report.
Jim Cramer provided his assessment of D-Wave, expressing reservations about its business model and referring to it as more of a 'science project' than a solid investment.
Former President Trump has imposed 100% tariffs on prescription drugs from companies that have not agreed to lower prices, a move aimed at incentivizing domestic production and reducing drug costs in the United States.
Regeneron Pharma (REGN) shares have risen after Jim Cramer publicly called it a good stock.
Jim Cramer expresses regret over not investing in Regeneron, saying, “I Should Have Pulled the Trigger on Regeneron.”
Regeneron and Sanofi have announced that their drug Dupixent has received a label expansion, allowing it to be used for the treatment of allergic fungal rhinosinusitis.
Biopharmaceutical company Regeneron has adopted Veeva Systems' Vault CRM platform to streamline customer relationship management and enhance commercial data integration.
Analysts are evaluating whether Biohaven's recent deal with Regeneron Pharmaceuticals could serve as a major catalyst for its drug development pipeline.
Major tech companies like Amazon and Microsoft reported strong earnings driven by significant investments in AI, while Apple warned of future supply constraints impacting Mac, iPhone, and iPad sales, leading to a projected slowdown in September-quarter growth.
Regeneron Pharmaceuticals announced a quarterly dividend of $0.94 per share. This financial declaration is a routine update for shareholders.
Hikaru Kuribayashi, an 18-year-old, won the top prize of $100,000 at the 2026 Regeneron International Science and Engineering Fair, crediting his love of origami.
Several MedTech and Biotech companies, including TransMedics Group, Insulet Corporation, and Regeneron Pharmaceuticals, have seen their stock price targets cut by analysts. This raises questions about their continued growth opportunities in the respective sectors.
Hedge funds are reportedly evaluating top AI-powered healthcare stocks, with Eli Lilly and Company (LLY) and Regeneron Pharmaceuticals, Inc. (REGN) being highlighted as potential investment opportunities in this sector.
An analysis evaluates whether Regeneron Pharmaceuticals, Inc. (REGN) is currently a good stock to buy for investors.
Quantinuum, Honeywell's quantum computing company, saw its shares jump 13% after an upsized IPO, signaling growing investor confidence in the quantum sector. The successful Nasdaq debut highlights increasing momentum in quantum computing.
Regeneron (REGN) has announced that the European Medicines Agency (EMA) has accepted its application for Otarmeni for review.
Wall Street analysts are offering predictions on whether Regeneron Pharmaceuticals stock will climb or sink, reflecting varying market sentiments.
SpaceX is reportedly preparing for the largest initial public offering (IPO) in history, with filings revealing details about its valuation and future ambitions. Elon Musk is set to retain significant control over the company, holding a majority of voting rights even after the public listing.
Several prominent stocks, including Regeneron, Dominion Energy, and Macy's, experienced notable price changes during premarket trading. Some shares were observed to be gapping down significantly before the market opened.
Regeneron Pharmaceuticals saw its stock decline after a melanoma study conducted by the company failed to meet its key endpoint, impacting investor confidence.
Billionaire investor Steve Cohen reportedly considers Regeneron Pharmaceuticals (REGN) to be among the best biotech stocks for investment.
An analysis provides insights into the performance and outlook of several pharmaceutical giants, highlighting Bristol Myers' legacy boost, Biogen's positive prospects, and Regeneron's uncertain future.
CTO outlined its 2026 core FFO and structured investment targets, while InvenTrust also raised its 2026 NAREIT FFO guidance. Separately, Regeneron provided an update on its EYLEA HD prefilled syringe decision and 2026 GAAP gross margin.
TD Cowen has increased its price target for Regeneron Pharmaceuticals, signaling optimism for the company's financial performance ahead of its fiscal first-quarter results.
The United States has approved the first gene therapy designed to treat a rare form of hearing loss. Following this landmark FDA approval, Regeneron plans to offer the therapy for free.
Sanofi and Regeneron's drug Dupixent has received approval, becoming the first biologic treatment available for children under 12 suffering from chronic spontaneous urticaria (CSU).
Telix Pharmaceuticals and Regeneron Pharmaceuticals have announced a strategic collaboration to co-develop novel radiopharmaceutical therapies, combining their expertise in oncology and drug development.
Regeneron's deep pipeline of potentially successful drugs helps to offset competitive risks in other areas.
Pharmaceutical company Regeneron has gained approval for an extended 20-week dosing regimen for its drug Eylea HD.
An article examines the investment potential of Regeneron Pharmaceuticals, Inc. (REGN) for prospective stock purchasers.
Several financial firms have issued new ratings, price targets, or coverage initiations for biotech and pharmaceutical companies including Beam Therapeutics, Krystal Biotech, 4D Molecular Therapeutics, BioMarin Pharmaceutical, Vertex Pharmaceuticals, CRISPR Therapeutics AG, Regeneron Pharmaceuticals, and UniQure.
Analysts are offering their latest comments and assessments regarding Regeneron Pharmaceuticals (REGN).
Regeneron has secured approval from the U.S. Food and Drug Administration (FDA) for its new therapy designed to treat a rare bone disorder.
Regeneron and Tenet are highlighted among the top healthcare companies that reported the highest earnings beats.
Regeneron anticipates low to mid-teens demand growth for its EYLEA HD product in the third and fourth quarters of 2026, driven by a push for prefilled syringes.
Several companies, including MarketAxess, Jones Lang LaSalle, APi Group, and Regeneron, have reported robust second-quarter earnings that largely surpassed analyst estimates for both EPS and revenue. Regeneron notably saw a rise in its stock following strong performance driven by its high-dose Eylea.
Incyte is positioning itself as a strong contender for biotech growth, making its case against established players like Regeneron.
Regeneron Pharmaceuticals expects to incur a pre-tax in-process research and development (IPR&D) charge of approximately $127 million in the second quarter.
RBC Capital has affirmed its 'Sector Perform' rating on Regeneron (REGN), providing reasons for its continued assessment of the biotechnology company.
Drugmaker Parabilis saw its shares soar by 67% following a successful initial public offering and placement that raised $745 million. The company, backed by Regeneron, experienced a significant surge after its record-setting IPO.
Alvotech is once again seeking US regulatory approval for its biosimilar versions of Johnson & Johnson's Simponi and Regeneron's Eylea. This marks another attempt by the company to bring these treatments to the American market.
The head of the World Health Organization (WHO) stated that the Ebola outbreak in the Democratic Republic of Congo is being complicated by ongoing conflict and insecurity, despite efforts to scale up testing and identify treatments. An Italian doctor who had contact with Ebola patients was admitted to a Rome hospital.
Regeneron has entered into a $2.32 billion collaboration agreement with Parabilis to develop new therapies targeting proteins previously considered 'undruggable.'
Regeneron's stock has fallen 10% following the failure of its Phase 3 melanoma trial, raising questions about the company's future prospects.
Drugmaker Regeneron saw its stock drop after its fianlimab-cemiplimab combination treatment for skin cancer did not achieve statistical significance in improving progression-free survival during late-stage trials.
Regeneron Pharmaceuticals experienced a decline in its stock value following the failure of a late-stage clinical trial for a melanoma treatment.
Piper Sandler has rated Regeneron (REGN) as 'Overweight,' highlighting its growth in the oncology sector.
US biotech giant Regeneron Pharmaceuticals has attributed a recent production pause and subsequent hit to its overall margin to unexpected facility repairs at its large manufacturing plant in Limerick, Ireland.
Regeneron Pharmaceuticals experienced a slide in its share price, even after reporting better-than-expected financial results for the first quarter.
The World Health Organization has given its approval for the first-ever malaria treatment specifically designed for infants. This marks a significant step in combating the disease in young children.
The U.S. Food and Drug Administration has approved the first gene therapy for inherited deafness, developed by Regeneron. This breakthrough treatment offers the potential to restore hearing in children with a rare form of genetic hearing loss.
Regeneron Pharmaceuticals (REGN) has announced a new collaboration agreement with Telix Pharmaceuticals Limited, signaling a joint effort in pharmaceutical development.
Sanofi and Regeneron's drug Dupixent has received approval in the European Union for treating young children suffering from chronic urticaria, expanding its use for pediatric patients.
Biotechnology company Regeneron Pharmaceuticals expects to incur approximately $102 million in pre-tax in-process research and development charges for the first quarter.
Piper Sandler has upgraded Regeneron Pharmaceuticals to an 'overweight' rating, citing strong performance from its drug Dupixent and the potential of its robust pipeline.
An analysis questions whether Regeneron Pharmaceuticals stock is underperforming relative to the broader Nasdaq index.
Regeneron has been granted FDA priority review for its therapy targeting a rare bone disorder, potentially accelerating its path to market.